BioVie Files S-1 for Up to $50M Best-Efforts Offering to Stave Off Cash Crunch
BIVI sits 70% above its 52-week low of $1.06.
Summary
BioVie Inc. filed an S-1 to raise up to $50 million in a best-efforts offering, a critical financing for the cash-strapped biotech as it nears key clinical data readouts.
Key Events · Financing and Capital Events · BIVI
-
Up to $50M Best-Efforts Offering
BioVie registered up to $50 million of Class A common stock and pre-funded warrants in a best-efforts offering with ThinkEquity as placement agent. No minimum offering amount is required, and the company may sell fewer than all securities offered.
-
Cash Runway Pressure
As of March 31, 2026, BioVie had $13.1 million in cash and used $14.9 million in operations over the prior nine months. The company has a going-concern warning and less than eight months of cash runway, making this offering critical to fund operations.
-
Dilution Risk for Existing Holders
If the full $50 million is raised at the current $1.80 stock price, approximately 27.8 million new shares would be issued, representing roughly 370% dilution to the existing 7.5 million shares outstanding. The actual dilution will depend on the final offering price and amount sold.
-
Placement Agent Terms
ThinkEquity will receive a 7.0% placement agent fee, a 0.5% non-accountable expense allowance, and warrants to purchase 5% of the aggregate shares sold at 125% of the public offering price. The company also granted a three-month right of first refusal for future equity offerings.
Analysis · BIVI · Life Sciences
Facing a going-concern warning and less than eight months of cash runway, clinical-stage biotech BioVie is attempting a survival raise of up to $50 million through a best-efforts offering. As of March 31, 2026, the company held $13.1 million in cash after burning $14.9 million in operations over the prior nine months. Without this capital, it risks running out of money before key Phase 2b Parkinson's data expected in late summer 2026. The best-efforts structure carries no guarantee of any funds raised, and the absence of a minimum offering amount adds execution risk. If completed, existing shareholders face significant dilution, especially at the current $1.80 stock price, which sits near the low end of the company's recent trading range.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35% of the 1333 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIVI was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6M. The 52-week trading range was $1.06 to $9.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.